Enanta Pharmaceuticals, Inc. (ENTA)
ENTA Stock Price Chart
Explore Enanta Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze ENTA price movements and trends.
ENTA Company Profile
Discover essential business fundamentals and corporate details for Enanta Pharmaceuticals, Inc. (ENTA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Mar 2013
Employees
131.00
Website
https://www.enanta.comCEO
Jay R. Luly
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
ENTA Financial Timeline
Browse a chronological timeline of Enanta Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 9 Feb 2026
Upcoming earnings on 24 Nov 2025
EPS estimate is -$1.13.
Earnings released on 11 Aug 2025
EPS came in at -$0.85 surpassing the estimated -$1.25 by +32.00%, while revenue for the quarter reached $18.31M , beating expectations by +14.67%.
Earnings released on 12 May 2025
EPS came in at -$1.06 falling short of the estimated -$1.04 by -1.92%, while revenue for the quarter reached $14.93M , missing expectations by -6.48%.
Earnings released on 10 Feb 2025
EPS came in at -$1.05 surpassing the estimated -$1.16 by +9.48%, while revenue for the quarter reached $16.96M , missing expectations by -1.68%.
Earnings released on 25 Nov 2024
EPS came in at -$1.36 falling short of the estimated -$1.16 by -17.24%, while revenue for the quarter reached $67.64M , beating expectations by +277.22%.
Earnings released on 5 Aug 2024
EPS came in at -$1.07 surpassing the estimated -$1.49 by +28.19%, while revenue for the quarter reached $17.97M , beating expectations by +0.96%.
Earnings released on 6 May 2024
EPS came in at -$1.47 falling short of the estimated -$1.26 by -16.67%, while revenue for the quarter reached $17.05M , beating expectations by +3.23%.
Earnings released on 7 Feb 2024
EPS came in at -$1.58 falling short of the estimated -$1.18 by -33.90%, while revenue for the quarter reached $18.00M , missing expectations by -17.98%.
Earnings released on 20 Nov 2023
EPS came in at -$1.33 surpassing the estimated -$2.11 by +36.97%, while revenue for the quarter reached $18.93M , missing expectations by -8.10%.
Earnings released on 7 Aug 2023
EPS came in at -$1.86 surpassing the estimated -$2.38 by +21.85%, while revenue for the quarter reached $18.89M , missing expectations by -8.56%.
Earnings released on 8 May 2023
EPS came in at -$1.79 surpassing the estimated -$1.91 by +6.28%, while revenue for the quarter reached $17.80M , missing expectations by -7.22%.
Earnings released on 7 Feb 2023
EPS came in at -$1.39 surpassing the estimated -$1.52 by +8.55%, while revenue for the quarter reached $23.59M , beating expectations by +0.14%.
Earnings released on 21 Nov 2022
EPS came in at -$1.27 surpassing the estimated -$1.37 by +7.30%, while revenue for the quarter reached $20.32M , missing expectations by -12.16%.
Earnings released on 8 Aug 2022
EPS came in at -$1.53 falling short of the estimated -$1.36 by -12.50%, while revenue for the quarter reached $19.48M , missing expectations by -5.68%.
Earnings released on 9 May 2022
EPS came in at -$1.63 falling short of the estimated -$1.43 by -13.99%, while revenue for the quarter reached $18.72M , missing expectations by -9.44%.
Earnings released on 8 Feb 2022
EPS came in at -$1.48 falling short of the estimated -$1.13 by -30.97%, while revenue for the quarter reached $27.65M , beating expectations by +1.03%.
Earnings released on 22 Nov 2021
EPS came in at -$1.22 surpassing the estimated -$1.31 by +6.87%, while revenue for the quarter reached $23.58M , missing expectations by -13.93%.
Earnings released on 5 Aug 2021
EPS came in at -$1.19 surpassing the estimated -$1.41 by +15.60%, while revenue for the quarter reached $21.62M , missing expectations by -1.08%.
Earnings released on 6 May 2021
EPS came in at -$1.09 falling short of the estimated -$0.94 by -15.96%, while revenue for the quarter reached $20.13M , beating expectations by +12.64%.
Earnings released on 8 Feb 2021
EPS came in at -$0.41 surpassing the estimated -$0.82 by +50.00%, while revenue for the quarter reached $31.74M , missing expectations by -23.16%.
Earnings released on 23 Nov 2020
EPS came in at -$0.55 surpassing the estimated -$0.92 by +40.22%, while revenue for the quarter reached $23.63M , beating expectations by +96.28%.
ENTA Stock Performance
Access detailed ENTA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.